Old Web
English
Sign In
Acemap
>
Paper
>
Eculizumab for atypical haemolytic-uraemic syndrome. How long should we maintain it?
Eculizumab for atypical haemolytic-uraemic syndrome. How long should we maintain it?
2019
Javier Munoz
Ana García García-Doncel
María Elisa Montero Escobar
Florentino Villanego Fernández
Irene Millan Ortega
Manuel Ceballos Guerrero
Keywords:
Pediatrics
Diabetes mellitus
Eculizumab
Medicine
Haemolytic-uraemic syndrome
Intensive care medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]